Melatonin and breast cancer: a prospective study

Area of Science:

• Endocrinology
• Oncology
• Epidemiology

Background:

• Animal studies suggest melatonin, a pineal hormone, may protect against breast cancer.
• Previous human studies on melatonin and breast cancer risk have yielded inconsistent results.
• A prospective nested case-control study was designed to investigate this association in British women.

Purpose of the Study:

• To determine if low endogenous melatonin levels are associated with an increased risk of developing breast cancer.
• To examine the relationship between urinary 6-sulfatoxymelatonin concentrations and breast cancer incidence.

Main Methods:

• Measured 6-sulfatoxymelatonin, a validated marker of melatonin, in 24-hour urine samples from 127 breast cancer patients and 353 matched controls.
• Utilized radioimmunoassay for metabolite quantification.
• Employed analyses of covariance and conditional logistic regression to assess associations, adjusting for potential confounders.

Main Results:

• No statistically significant differences in urinary 6-sulfatoxymelatonin concentrations were found between breast cancer cases and control subjects in premenopausal or postmenopausal women.
• Multivariable analysis combining pre- and postmenopausal women showed no significant association between melatonin metabolite levels (categorized by tertiles) and breast cancer risk.
• Odds ratios for breast cancer were 0.95 (middle vs. lowest tertile) and 0.99 (highest vs. lowest tertile), with overlapping confidence intervals.

Conclusions:

• The study found no strong evidence to support an association between melatonin levels and breast cancer risk in the studied population.
• Results suggest that melatonin may not play a significant role in breast cancer etiology in humans, contrary to some animal data.